Impact of Delayed Cost-Improvement Initiatives on Dental Profit
First written in FY2018-Q3. 6 of 8 entries say "Mitigated", first in FY2019-Q1. Latest entry: FY2023.
1 other company's latest entry also says "Mitigated".
- FY2023MitigatedAnnual report
「The cost of sales ratio improved by 1.4 percentage points year on year as the impact of inventory disposals carried out in the same period of the previous year to review appropriate inventory levels for Ailess needles ended, while productivity also improved.」
The adverse impact of inventory disposals in the same period of the previous year on the cost ratio ended, and the cost of sales ratio improved by 1.4 percentage points with the added benefit of improved productivity. - FY2022-Q1MitigatedAnnual report
「As a result of higher revenue and an improvement in the cost-of-sales ratio, among other factors, segment profit (operating profit) was ¥487 million, up 22.8% year on year.」
Regarding cost improvement, which had previously been identified as an issue, the company cited an improvement in the cost of sales ratio and a 22.8% increase in segment profit from Ailess needle-related products. - FY2020MitigatedAnnual report
「The cost of sales ratio improved following the discontinuation of sales of dental operating microscopes and other products and changes in the product mix, with the cost of sales ratio improving 1.6 percentage points from the previous fiscal year to 35.0%.」
Regarding cost improvement, which had been identified as an issue through the previous fiscal year, the company stated that the cost of sales ratio improved by 1.6 percentage points due to changes in the product mix following the discontinuation of product sales and other factors. - FY2019-Q3MitigatedAnnual report
「Mainly because cost ratios improved through the transfer of production processes to Vietnam and a review of production processes」
In response to the delays in cost improvement activities cited through the previous fiscal year, the company cited improved cost ratios resulting from the transfer of production processes to Vietnam and a review of production processes. - FY2019-Q2MitigatedAnnual report
「Meanwhile, segment profit (operating profit) was ¥816 million, up 13.9% year on year, mainly because sales increased for products whose cost ratios improved as a result of advancing the transfer of production processes to Vietnam.」
For the dental-related products for which delays in cost improvement activities had been cited, the company reported increased sales of products whose cost ratios improved following the transfer of production processes to Vietnam, as well as a 13.9% increase in segment profit. - FY2019-Q1MitigatedAnnual report
「Meanwhile, segment profit (operating profit) was ¥508 million, up 21.8% year on year, mainly because sales increased for products whose cost ratios improved as production processes were transferred to Vietnam and the benefits of higher production volumes took effect, among other factors.」
In response to the delays in cost improvement activities cited in the previous quarter and previous fiscal year, the company cited improved cost ratios resulting from the transfer of production processes and the effects of increased production. - FY2018RestatedAnnual report
「Although net sales increased, segment profit (operating profit) was ¥1,465 million, up 0.2% year on year, mainly because cost improvement initiatives were delayed and sales of the low-margin digital workflow increased, among other factors.」
Delays in cost improvement activities were again cited as a factor explaining profit from dental-related products for the full fiscal year. - FY2018-Q3First statedAnnual report
「Although revenue increased, segment profit (operating profit) was ¥1,093 million, up 9.1% year on year, due to delays in cost improvement activities.」
For dental-related products, revenue increased, while delays in cost improvement activities were cited as a factor explaining segment profit for the first time.